Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00905
|
|||||
Drug Name |
Sotalol
|
|||||
Synonyms |
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid; Beta-Cardone; Betapace (TN); Betapace AF (TN); D,l-Sotalol; Darob mite; Darob mite (TN); MJ-1999; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol Monohydrochloride; Sotalol [INN:BAN]; Sotalolum; Sotalolum [INN-Latin]
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Maintenance of normal sinus rhythm [ICD11: BC81.3] | Approved | [1] | |||
Therapeutic Class |
Antiarrhythmic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C12H20N2O3S
|
|||||
Canonical SMILES |
CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
|
|||||
InChI |
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
|
|||||
InChIKey |
ZBMZVLHSJCTVON-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 3930-20-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 272.37 | Topological Polar Surface Area | 86.8 | ||
Heavy Atom Count | 18 | Rotatable Bond Count | 6 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
0.2
|
|||||
PubChem CID | ||||||
ChEBI ID |
CHEBI:63622
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
References | ||||||
1 | Sotalol was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.